Annual report pursuant to Section 13 and 15(d)

Collaboration and Research Arrangements - Collaboration Agreement (Details)

v3.19.3.a.u2
Collaboration and Research Arrangements - Collaboration Agreement (Details) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 17, 2019
Jan. 08, 2018
Jan. 31, 2020
Nov. 30, 2019
Jan. 31, 2018
Dec. 31, 2019
Dec. 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized           $ 2,000,000 $ 2,100,000
Deferred revenue           28,378,000 10,202,000
Deferred revenue, long-term           22,639,000 8,276,000
GBT [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Deferred revenue           20,000,000 0
GBT [Member] | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Initial period of research term 3 years            
Additional extension period for research term upon mutual agreement 1 year            
Upfront payment receivable $ 20,000,000            
Reimbursements receivable of full-time employee and out-of-pocket costs and expenses $ 40,000,000            
Agreement termination, prior written notice if notice delivered during the research term 9 months            
Agreement termination, prior written notice if notice delivered after the expiration or termination of the research term 90 days            
Total transaction price $ 60,000,000            
Upfront non-refundable and non-creditable payment 20,000,000            
Reimbursable costs $ 40,000,000            
Accounts receivable           20,000,000  
Revenue recognized           0  
Deferred revenue           20,000,000  
Deferred revenue, short-term           4,500,000  
Deferred revenue, long-term           15,500,000  
GBT [Member] | Collaboration Agreement | Subsequent Event              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collection from collaborators     $ 20,000,000        
GBT [Member] | Collaboration Agreement | Maximum [Member]              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Period of extension of initial research term 2 years            
Receivable from option exercise, development, regulatory, commercialization and sales-based milestones per product candidate and product resulting $ 315,000,000            
Incyte              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Revenue recognized           2,000,000 2,100,000
Deferred revenue           8,378,000 $ 10,202,000
Deferred revenue, short-term           1,300,000  
Deferred revenue, long-term           $ 7,100,000  
Incyte | Collaboration Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Total transaction price   $ 12,300,000   $ 12,800,000      
Upfront non-refundable and non-creditable payment       2,500,000      
Up-front consideration         $ 10,000,000    
Up-front consideration, cash         2,500,000    
Up-front consideration, pre-paid research funding         $ 7,500,000    
Prepaid research amount       7,500,000      
Premium paid on equity investment       2,300,000      
Collaboration agreement additional consideration incurred       $ 500,000